Phaseline

Companies › Cook MyoSite

Cook MyoSite: clinical trials, targets and expected readouts

1 active drug program in 2 registered trials: 2 Phase 3; Gastroenterology, Genitourinary; next expected readout Nov 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
AMDC-USR (iltamiocel)
Autologous muscle-derived cells injected into urinary sphincter
–Phase 3Stress Urinary Incontinence; Fecal IncontinenceNov 2026

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT03104517AMDC-USR (iltamiocel)Phase 3Stress Urinary IncontinenceGenitourinaryNov 2026
NCT05776277AMDC-USR (iltamiocel)Phase 3Fecal IncontinenceGastroenterologyDec 2026

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

Urotronic GIE Medical Prokidney Taisho Pharmaceutical YolTech Therapeutics

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.